Cogent Biosciences Inc (COGT) concluded trading on Thursday at a closing price of $8.34, with 3.98 million shares of worth about $33.2 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -7.13% during that period and on December 12, 2024 the price saw a loss of about -10.03%. Currently the company’s common shares owned by public are about 110.46M shares, out of which, 88.93M shares are available for trading.
Stock saw a price change of -7.23% in past 5 days and over the past one month there was a price change of -19.65%. Year-to-date (YTD), COGT shares are showing a performance of 41.84% which increased to 87.42% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $3.90 but also hit the highest price of $12.61 during that period. The average intraday trading volume for Cogent Biosciences Inc shares is 1.28 million. The stock is currently trading -9.46% below its 20-day simple moving average (SMA20), while that difference is down -20.08% for SMA50 and it goes to -6.50% lower than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Cogent Biosciences Inc (NASDAQ: COGT) currently have 110.46M outstanding shares and institutions hold larger chunk of about 91.35% of that.
The stock has a current market capitalization of $921.25M and its 3Y-monthly beta is at 1.72. It has posted earnings per share of -$2.48 in the same period. It has Quick Ratio of 6.44 while making debt-to-equity ratio of 0.06. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for COGT, volatility over the week remained 12.25% while standing at 7.08% over the month.
Stock’s fiscal year EPS is expected to drop by -0.41% while it is estimated to increase by 4.93% in next year.
Coverage by Robert W. Baird stated Cogent Biosciences Inc (COGT) stock as a Neutral in their note to investors on February 26, 2024, suggesting a price target of $8 for the stock. On February 08, 2024, Citigroup Initiated their recommendations, while on December 11, 2023, Wedbush Downgrade their ratings for the stock with a price target of $5. Stock get an Overweight rating from JP Morgan on December 08, 2023.
